Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 2,339 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all

Conditions: Hereditary Angioedema
Interventions: CINRYZE; Biological
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 7
States / cities: Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ 28431754, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Interventions: mistletoe extract, gemcitabine hydrochloride; Dietary Supplement · Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions: Satralizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetes Mellitus
Interventions: Insulin; Drug
Lead sponsor: QDose Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Volunteers
Interventions: Risdiplam, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Healthy
Interventions: HPG1860; Drug
Lead sponsor: Hepagene (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions: 4A10; Drug
Lead sponsor: Allterum Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BBT-877, Single dose, Placebo group, BBT-877, Multiple doses; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2, NIDDM
Interventions: PF-04937319, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Miami, Florida • South Miami, Florida • Cincinnati, Ohio

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: Concizumab, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Torrance, California • Indianapolis, Indiana • Iowa City, Iowa + 5 more

Conditions: Hot Flashes
Interventions: Gabapentin Extended Release tablets, Gabapentin; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more

Conditions: Primary Hyperoxaluria Type 1, Primary Hyperoxaluria
Interventions: Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions: Mepolizumab, Reslizumab, Placebo; Biological
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Uncontrolled Gout, Chronic Gout
Interventions: Pegloticase, Methotrexate (MTX); Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more

Conditions: Parkinson's Disease
Interventions: HNC364; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions: CRD-4730, Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Morrisville, North Carolina • Houston, Texas + 2 more

Conditions: Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: HM12460A, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Immune System Diseases, Autoimmunity
Interventions: HIB210, Placebo; Drug
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Hematopoietic Syndrome Due to Acute Radiation Syndrome
Interventions: HemaMax, Placebo; Biological · Drug
Lead sponsor: Neumedicines Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hereditary Angioedema
Interventions: Navenibart; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more

Conditions: Muscular Atrophy, Spinal
Interventions: RO6885247, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Stanford, California • Orlando, Florida • Chicago, Illinois + 3 more

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: ABO-101; Drug
Lead sponsor: Arbor Biotechnologies; Industry
Eligibility: 6 Years to 64 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2043
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: EDP-978, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

A Phase 2 Study of CRD-4730 in CPVT

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults